3 results
The primary objective is to investigate the efficacy, safety and tolerability of RV 001 (a fully human anti-IGF-1R antibody) administered q3W for 6 months, in comparison to placebo, in the treatment of patients suffering from active TED.Secondary…
Primary goal:The cure at 12 monthsSecondary goals:1. Cough Stress Test (HST): objective endpoint2. Question 3 of the UDI-6 questionnaire: subjective endpoint3. Primary endpoint at 6 weeks, 6 months, and 36 months 24maanden4. Reduction of urine loss…
To demonstrate superior efficacy and non-inferior safety of the SELUTION SLR 014 DEB compared to PTA (uncoated balloon) in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.